Transgene SA (TNG.PA)
EUR 0.71
(-1.8%)
EUR 0.71
(-1.8%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | -14.4 Million EUR | -637.41% |
| 2022 | -1.95 Million EUR | 5.47% |
| 2021 | -2.06 Million EUR | -34550.0% |
| 2020 | 6000.00 EUR | -99.96% |
| 2019 | 15.32 Million EUR | -58.58% |
| 2018 | 36.98 Million EUR | -8.74% |
| 2017 | 40.53 Million EUR | 0.36% |
| 2016 | 40.38 Million EUR | 21.92% |
| 2015 | 33.12 Million EUR | 1.31% |
| 2014 | 32.69 Million EUR | 8.34% |
| 2013 | 30.17 Million EUR | 39.1% |
| 2012 | 21.69 Million EUR | 1351.88% |
| 2011 | -1.73 Million EUR | -25.67% |
| 2010 | -1.37 Million EUR | 97.87% |
| 2009 | -64.69 Million EUR | -189.95% |
| 2008 | -22.31 Million EUR | -371766.67% |
| 2007 | -6000.00 EUR | 99.97% |
| 2006 | -20.32 Million EUR | 0.0% |
| 2004 | -9.59 Million EUR | 67.37% |
| 2003 | -29.4 Million EUR | 39.5% |
| 2002 | -48.6 Million EUR | 25.87% |
| 2001 | -65.56 Million EUR | -194.46% |
| 2000 | -22.26 Million EUR | 49.97% |
| 1999 | -44.5 Million EUR | 28.02% |
| 1998 | -61.82 Million EUR | -522.68% |
| 1997 | -9.92 Million EUR | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q2 | -15.23 Million EUR | 0.0% |
| 2023 Q1 | 7.85 Million EUR | 501.74% |
| 2023 Q4 | -14.4 Million EUR | -3804.11% |
| 2023 Q2 | -1.88 Million EUR | -123.95% |
| 2023 Q3 | 389 Thousand EUR | 120.69% |
| 2023 FY | -14.4 Million EUR | -637.41% |
| 2022 Q3 | 7.92 Million EUR | 301.32% |
| 2022 FY | -1.95 Million EUR | 5.47% |
| 2022 Q4 | -1.95 Million EUR | -124.66% |
| 2022 Q2 | -3.93 Million EUR | -148.68% |
| 2022 Q1 | 8.08 Million EUR | 491.15% |
| 2021 Q2 | -6.95 Million EUR | -230.74% |
| 2021 FY | -2.06 Million EUR | -34550.0% |
| 2021 Q1 | 5.31 Million EUR | 88533.33% |
| 2021 Q3 | 9.44 Million EUR | 235.83% |
| 2021 Q4 | -2.06 Million EUR | -121.89% |
| 2020 Q1 | 20.37 Million EUR | 32.99% |
| 2020 Q2 | 8.92 Million EUR | -56.19% |
| 2020 Q3 | 11.82 Million EUR | 32.47% |
| 2020 FY | 6000.00 EUR | -99.96% |
| 2020 Q4 | 6000.00 EUR | -99.95% |
| 2019 Q2 | 17.14 Million EUR | -53.94% |
| 2019 FY | 15.32 Million EUR | -58.58% |
| 2019 Q3 | 26 Million EUR | 51.67% |
| 2019 Q4 | 15.32 Million EUR | -41.08% |
| 2019 Q1 | 37.22 Million EUR | 0.63% |
| 2018 FY | 36.98 Million EUR | -8.74% |
| 2018 Q2 | 34.92 Million EUR | -35.56% |
| 2018 Q1 | 54.2 Million EUR | 33.72% |
| 2018 Q4 | 36.98 Million EUR | -34.43% |
| 2018 Q3 | 56.41 Million EUR | 61.52% |
| 2017 Q4 | 40.53 Million EUR | -31.6% |
| 2017 Q2 | 39.23 Million EUR | -30.1% |
| 2017 FY | 40.53 Million EUR | 0.36% |
| 2017 Q3 | 59.25 Million EUR | 51.02% |
| 2017 Q1 | 56.13 Million EUR | 39.0% |
| 2016 FY | 40.38 Million EUR | 21.92% |
| 2016 Q3 | 57.01 Million EUR | 43.21% |
| 2016 Q2 | 39.81 Million EUR | -29.43% |
| 2016 Q1 | 56.41 Million EUR | 70.31% |
| 2016 Q4 | 40.38 Million EUR | -29.16% |
| 2015 Q2 | 40.69 Million EUR | -27.0% |
| 2015 FY | 33.12 Million EUR | 1.31% |
| 2015 Q4 | 33.12 Million EUR | -32.89% |
| 2015 Q3 | 49.35 Million EUR | 21.3% |
| 2015 Q1 | 55.74 Million EUR | 70.5% |
| 2014 Q4 | 32.69 Million EUR | -31.28% |
| 2014 Q3 | 47.58 Million EUR | 33.79% |
| 2014 FY | 32.69 Million EUR | 8.34% |
| 2014 Q2 | 35.56 Million EUR | -28.87% |
| 2014 Q1 | 50 Million EUR | 65.69% |
| 2013 Q1 | 37.72 Million EUR | 73.9% |
| 2013 FY | 30.17 Million EUR | 39.1% |
| 2013 Q4 | 30.17 Million EUR | -30.66% |
| 2013 Q3 | 43.52 Million EUR | 58.07% |
| 2013 Q2 | 27.53 Million EUR | -27.02% |
| 2012 FY | 21.69 Million EUR | 1351.88% |
| 2012 Q4 | 21.69 Million EUR | 453.51% |
| 2012 Q2 | -10.69 Million EUR | 0.0% |
| 2012 Q3 | -6.13 Million EUR | 42.62% |
| 2011 Q2 | -13.79 Million EUR | 0.0% |
| 2011 Q4 | -1.73 Million EUR | 0.0% |
| 2011 FY | -1.73 Million EUR | -25.67% |
| 2010 FY | -1.37 Million EUR | 97.87% |
| 2010 Q2 | -1.21 Million EUR | 0.0% |
| 2010 Q4 | -1.37 Million EUR | 0.0% |
| 2009 Q2 | -81.63 Million EUR | 0.0% |
| 2009 FY | -64.69 Million EUR | -189.95% |
| 2009 Q4 | -64.69 Million EUR | 0.0% |
| 2008 FY | -22.31 Million EUR | -371766.67% |
| 2008 Q4 | -22.31 Million EUR | 0.0% |
| 2007 FY | -6000.00 EUR | 99.97% |
| 2006 FY | -20.32 Million EUR | 0.0% |
| 2005 Q2 | -4.47 Million EUR | 0.0% |
| 2004 FY | -9.59 Million EUR | 67.37% |
| 2004 Q4 | -9.59 Million EUR | 0.0% |
| 2004 Q2 | -24.81 Million EUR | 16.23% |
| 2004 Q1 | -29.62 Million EUR | -0.76% |
| 2003 Q3 | -40.73 Million EUR | 9.16% |
| 2003 Q4 | -29.4 Million EUR | 27.82% |
| 2003 Q2 | -44.84 Million EUR | 10.06% |
| 2003 FY | -29.4 Million EUR | 39.5% |
| 2003 Q1 | -49.86 Million EUR | -2.6% |
| 2002 Q4 | -48.6 Million EUR | 14.3% |
| 2002 Q2 | -61.66 Million EUR | 7.31% |
| 2002 Q1 | -66.52 Million EUR | -1.48% |
| 2002 FY | -48.6 Million EUR | 25.87% |
| 2002 Q3 | -56.7 Million EUR | 8.03% |
| 2001 Q3 | -78.17 Million EUR | 6.87% |
| 2001 Q4 | -65.56 Million EUR | 16.14% |
| 2001 FY | -65.56 Million EUR | -194.46% |
| 2001 Q1 | -24.7 Million EUR | -10.96% |
| 2001 Q2 | -83.94 Million EUR | -239.8% |
| 2000 Q1 | -43.75 Million EUR | 1.69% |
| 2000 FY | -22.26 Million EUR | 49.97% |
| 2000 Q3 | -34.79 Million EUR | 15.34% |
| 2000 Q4 | -22.26 Million EUR | 36.01% |
| 2000 Q2 | -41.1 Million EUR | 6.05% |
| 1999 FY | -44.5 Million EUR | 28.02% |
| 1999 Q4 | -44.5 Million EUR | 0.0% |
| 1998 FY | -61.82 Million EUR | -522.68% |
| 1998 Q4 | -61.82 Million EUR | 0.0% |
| 1997 FY | -9.92 Million EUR | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| ABIONYX Pharma SA | -714 Thousand EUR | -1918.067% |
| ABIVAX Société Anonyme | -196.47 Million EUR | 92.666% |
| Adocia SA | 127 Thousand EUR | 11445.669% |
| Aelis Farma SA | -16.19 Million EUR | 11.012% |
| Biophytis S.A. | 2.7 Million EUR | 633.074% |
| Advicenne S.A. | 12.17 Million EUR | 218.349% |
| genOway Société anonyme | 2.97 Million EUR | 584.667% |
| IntegraGen SA | -709.74 Thousand EUR | -1930.154% |
| Medesis Pharma S.A. | 1.15 Million EUR | 1344.075% |
| Neovacs S.A. | -237.08 Thousand EUR | -5977.516% |
| NFL Biosciences SA | -2.27 Million EUR | -533.121% |
| Plant Advanced Technologies SA | 4.35 Million EUR | 430.746% |
| Quantum Genomics Société Anonyme | -830.54 Thousand EUR | -1634.879% |
| Sensorion SA | 1.37 Million EUR | 1145.477% |
| Theranexus Société Anonyme | 2.44 Million EUR | 689.529% |
| TME Pharma N.V. | -1.07 Million EUR | -1235.403% |
| Valbiotis SA | -18.13 Million EUR | 20.563% |
| TheraVet SA | 12.78 Thousand EUR | 112802.386% |
| Valerio Therapeutics Société anonyme | 2.18 Million EUR | 760.963% |
| argenx SE | -1.83 Billion EUR | 99.215% |
| BioSenic S.A. | 28.04 Million EUR | 151.38% |
| Celyad Oncology SA | -6.1 Million EUR | -136.136% |
| DBV Technologies S.A. | -114.95 Million USD | 87.466% |
| Galapagos NV | -157.2 Million EUR | 90.834% |
| Genfit S.A. | -7.61 Million EUR | -89.318% |
| GeNeuro SA | 5.91 Million EUR | 343.791% |
| Hyloris Pharmaceuticals SA | -25.11 Million EUR | 42.621% |
| Innate Pharma S.A. | -30.71 Million EUR | 53.083% |
| Inventiva S.A. | 10.48 Million EUR | 237.372% |
| MaaT Pharma SA | -10.2 Million EUR | -41.195% |
| MedinCell S.A. | 39.5 Million EUR | 136.478% |
| Nanobiotix S.A. | -24.71 Million EUR | 41.706% |
| Onward Medical N.V. | -12.89 Million EUR | -11.75% |
| Oryzon Genomics S.A. | 1.43 Million EUR | 1107.387% |
| OSE Immunotherapeutics SA | 27.12 Million EUR | 153.113% |
| Oxurion NV | 10.71 Million EUR | 234.538% |
| Pharming Group N.V. | 99.4 Million EUR | 114.496% |
| Poxel S.A. | 44.55 Million EUR | 132.337% |
| GenSight Biologics S.A. | 16.29 Million EUR | 188.431% |
| Financière de Tubize SA | 78.62 Million EUR | 118.326% |
| UCB SA | 2.17 Billion EUR | 100.662% |
| Valneva SE | 82.73 Million EUR | 117.416% |
| Vivoryon Therapeutics N.V. | -18.52 Million EUR | 22.214% |